Journal Watch

Dr. Yogesh Waikar
2022 Annals of Pediatric Gastroenterology & Hepatology  
Early diagnosis and treatment is required to improve clinical outcome in neonatal cholestasis syndrome. Neonatal Hepatopathy and Cholangiopathy are predominantly considered in this spectrum. Recent advances in this field are making the algorithmic approach more decisive. Serum matrix metalloproteinase-7 (MMP-7) is suggested to have discriminatory features for infants with Biliary Atresia. MMP-7, a protease involved in intercellular signaling through breakdown of extracellular matrix. The study
more » ... oncludes that serum MMP-7 assay has high sensitivity and specificity to differentiate Biliary Atresia from other neonatal cholestasis. The area under the curve of MMP-7 for the diagnosis of Biliary Atresia(BA) was 0.9900 with a cutoff value of 52.85 ng/mL; the diagnostic sensitivity and specificity are 98.67% and 95.00%, respectively, with a negative predictive value of 98.28%. The diagnosis of BA was made by the presence of fibrosing obstruction of extrahepatic biliary remnants excised after intraoperative cholangiography. The authors studied MMP-7 among healthy controls (n=72 with 54 <6 months) and among 135 with cholestasis (75 w i t h B A , 6 0 w i t h n o n -B A ) . M e d i a n concentration for MMP-7 was 2.86 ng/mL in healthy controls, 11.47 ng/mL for non-BA cholestasis, and 121.1 ng/mL for BA. The predictive value for MMP-7 was particularly impressive, 74 of 75 BA subjects were correctly identified as having BA. Only 3 non-BA patients
doi:10.5005/jp-journals-11009-0016 fatcat:coip753vkrdxthgnyrzjs36zeq